ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Inhibition of IP6K1 suppresses NPA formation via platelet short-chain polyphosphate polymers in necrotizing enterocolitis.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotizing enterocolitis (NEC) is a life-threatening intestinal inflammatory disease in preterm infants. Inositol hexakisphosphate kinase 1 (IP6K1) regulates platelet polyphosphate (polyP) homeostasis, yet its roles in NEC remain unclear.
objectiveThis study aimed to investigate the regulatory mechanism of platelet IP6K1 in neutrophil-platelet aggregate (NPA) formation and NEC pathogenesis, and to evaluate the therapeutic potential of IP6K1 inhibition.
methodsClinical samples from patients with NEC were analyzed to assess circulating mitochondrial DNA, anticardiolipin IgG levels, platelet alterations, platelet cell death patterns, and NPA formation. A mouse model of NEC was used to evaluate the effects of genetic IP6K1 deficiency and pharmacological IP6K inhibition with TNP on survival, intestinal injury, neutrophil infiltration, neutrophil extracellular trap (NET) formation, and inflammatory responses. Mechanistic experiments were performed using exogenous polyP supplementation and P-selectin neutralization
resultsPatients with NEC exhibited significantly increased circulating mitochondrial DNA levels, elevated anticardiolipin IgG levels, enhanced NPA formation, reduced platelet counts, abnormal platelet morphological parameters, and platelet pyroptosis as the predominant mode of cell death. In NEC mice, both IP6K1 deficiency and TNP treatment improved survival, preserved intestinal mucosal architecture, reduced disease severity, and markedly attenuated neutrophil infiltration and NET formation. Mechanistically, IP6K1 promoted NPA formation and downstream inflammatory responses by regulating the release of platelet-derived short-chain polyP. Exogenous polyP supplementation restored the impaired NPA formation observed in IP6K1⁻/⁻ mice. Moreover, P-selectin neutralization suppressed NPA formation and reduced NET production in inflamed intestinal tissues.
conclusionPlatelet IP6K1 is a key regulator of NPA formation and NET release in NEC through its control of platelet-derived short-chain polyP. Targeting IP6K1 may represent a promising therapeutic strategy for mitigating local and systemic inflammation in severe NEC.
Indexed as
Identifiers
42323451What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.